Efficacy of Cilostazol on Uncontrolled Coronary Vasospastic Angina: A Pilot Study

Cardiovascular Therapeutics

Volumn 31, Issue 3, 2013, Pages 179-185

  Yoo, Sang Yong ^a   Song, Sung Gook ^b   Lee, Jae Hwan ^c   Shin, Eun Seok ^d   Kim, Jeong Su ^e   Park, Yong Hyun ^e   Kim, Jun ^e   Chun, Kook Jin ^e   Kim, June Hong ^e  

^a University of Ulsan College of Medicine   (South Korea)

^b HanMaeum Hopspital Changwon City ^*  (South Korea)

^c Chungnam National University College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Yangsan Hospital   (South Korea)

Author keywords

Cilostazol; Coronary vasospasm; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; DILTIAZEM; ERGOMETRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; NITRIC ACID DERIVATIVE;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY SPASM; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HEART PALPITATION; HUMAN; MALE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; PROVOCATION TEST; RATING SCALE; TACHYCARDIA; TREATMENT DURATION;

ADULT; AGED; ANGINA PECTORIS; CORONARY VASOSPASM; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 3 INHIBITORS; PILOT PROJECTS; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 84876489534     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2012.00312.x     Document Type: Article

References (17)

1. JCS joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): Digest version. Circ J 2010;74:1745-1762.
2. Zhang X, Hintze TH. cAMP signal transduction cascade, a novel pathway for the regulation of endothelial nitric oxide production in coronary blood vessels. Arterioscler Thromb Vasc Biol 2001;21:797-803.
3. Nakamura T, Houchi H, Minami A, et al. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci 2001;69:1709-1715.
4. Matsumoto T, Noguchi E, Ishida K, Nakayama N, Kobayashi T, Kamata K. Cilostazol improves endothelial dysfunction by increasing endothelium-derived hyperpolarizing factor response in mesenteric arteries from Type 2 diabetic rats. Eur J Pharmacol 2008;599:102-109.
5. Song JK, Park SW, Kang DH, et al. Safety and clinical impact of ergonovine stress echocardiography for diagnosis of coronary vasospasm. J Am Coll Cardiol 2000;35:1850-1856.
6. Cote C, Lerman J, Todres ID. A practice of anesthesia for infants and children . Mumbai: Elsevier Health Sciences, 2009.
7. Gaspardone A, Tomai F, Versaci F, et al. Coronary artery stent placement in patients with variant angina refractory to medical treatment. Am J Cardiol 1999;84:96-98, A98.
8. Kanlop N, Chattipakorn S, Chattipakorn N. Effects of cilostazol in the heart. J Cardiovasc Med (Hagerstown) 2011;12:88-95.
9. Jennings LK, Saucedo JF. Antiplatelet and anticoagulant agents: Key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. Curr Opin Cardiol 2008;23:302-308.
10. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-1149.
11. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993;90:8474-8478.
12. Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006;189:350-357.
13. Nakamura T, Houchi H, Minami A, et al. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci 2001;69:1709-1715.
14. Kambayashi J, Liu YG, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003;9:2289-2302.
15. Matsumoto M. Cilostazol in secondary prevention of stroke: Impact of the cilostazol stroke prevention study. Atheroscler Suppl 2005;6:33-40.
16. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999;34:631-638.
17. Watanabe K, Ikeda S, Komatsu J, et al. Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. Am J Cardiol 2003;92:21-25.